Analysts' Actions: ANR BMY CAT DIS
NEW YORK (
) --
CHANGE IN RATINGS
Arch Coal
(ACI) - Get Albertsons Companies, Inc. Class A Report
was upgraded at BMO Capital from underperform to market perform. $8 price target. Met coal fundamentals appear to be improving, BMO said.
Alpha Natural
(ANR)
was upgraded at BMO from underperform to market perform. $8 price target. Estimates were also increased, given the company's new guidance, BMO said.
Arotech
(ARTX) - Get Arotech Corporation Report
upgraded to hold at TheStreet Ratings.
First PacTrust Bancorp
(BANC) - Get Banc of California Incorporated Report
upgraded to buy at TheStreet Ratings.
TheStreet Recommends
BB&T
(BBT) - Get BB&T Corporation Report
was upgraded at Bank of America/Merrill Lynch to buy. Stock is attractive, following a 15% pullback, BofA/Merrill said. $32 price target.
Berry Plastics
(BERY) - Get Berry Global Group Inc Report
was initiated with an outperform rating at Wells Fargo. Company offers innovative products and can pay down debt, Wells Fargo said.
Bristol-Myers Squibb
(BMY) - Get Bristol-Myers Squibb Company Report
was downgraded at BMO Capital to market perform from outperform. $37 price target. A number of pipeline setbacks this year, BMO Capital said.
Caterpillar
(CAT) - Get Caterpillar Inc. Report
was downgraded at JP Morgan from overweight to neutral. $90 price target. Company has high inventory levels and faces lower mining spending, JP Morgan said.
Comerica
(CMA) - Get Comerica Incorporated Report
was upgraded at Citigroup from sell to neutral. $28 price target. Stock is down 11% over the past seven months, Citi said.
Disney
(DIS) - Get Walt Disney Company Report
was upgraded at Citi from neutral to buy. $54 price target. Recent acquisitions should boost future growth, Citi said.
Garmin
(GRMN) - Get Garmin Ltd. Report
was downgraded at Goldman Sachs from neutral to sell. $34 price target. Company is seeing lower demand for personal navigation and fitness devices, Goldman said.
Hibbett Sports
(HIBB) - Get Hibbett Inc Report
was upgraded at Needham from hold to buy. Stock is down about 15% from its recent highs, Needham said. $61 price target.
JC Penney
(JCP) - Get J. C. Penney Company, Inc. Report
was downgraded at Credit Suisse from neutral to underperform. $15 price target. Estimates were also cut, as management is struggling to turn the business around, Credit Suisse said.
Johnson & Johnson
(JNJ) - Get Johnson & Johnson Report
was downgraded at Jefferies to hold from buy. $75 price target. Easy money has been made, Jefferies said.
Merck
(MRK) - Get Merck & Co., Inc. Report
was upgraded at BMO Capital to outperform from market perform. $50 price target. Positive data from two early-stage products, BMO Capital said.
Nelnet
(NNI) - Get Nelnet, Inc. Class A Report
was upgraded at Credit Suisse from neutral to outperform. $33 price target. Estimates were also boosted, given loan purchases and higher realized net interest margin, Credit Suisse said.
NYSE Euronext
(NYX)
was upgraded at Stifel Nicolaus from hold to buy. $27 price target. Stock is attractively valued at a 52-week low, Stifel Nicolaus said.
Telephone & Data
(TDS) - Get Telephone and Data Systems, Inc. Report
was upgraded at Citigroup from neutral to buy. $27 price target. Management is selling assets while it is faced with with increased competition, Citi said.
Tripadvisor
(TRIP) - Get TripAdvisor, Inc. Report
was upgraded at Morgan Stanley from underweight to overweight. $41 price target. Company is changing its monetization strategy and remains leveraged to higher hotel shopper growth, Morgan Stanley said.
US Cellular
(USM) - Get United States Cellular Corp Report
was upgraded at Citigroup from neutral to buy. $42 price target. Wireless asset purchase should be accretive to shareholder value, Citi said.
Vertex Pharmaceuticals
(VRTX) - Get Vertex Pharmaceuticals Incorporated Report
was downgraded at Credit Suisse from outperform to neutral. $48 price target. Company will likely see lower Incivek sales, Credit Suisse said.
Western Union
(WU) - Get Western Union Company Report
was upgraded at DA Davidson to neutral from underperform. $13 price target. At current prices, downside appears minimal, DA Davidson said.
STOCK COMMENTS / EPS CHANGES
Ameren
(AEE) - Get Ameren Corporation Report
estimates, target reduced at UBS. AEE estimates were cut through 2013, UBS said. Company is seeing slower usage trends. Neutral rating and new $32 price target.
Citigroup
(C) - Get Citigroup Inc. Report
added to US 1 List at BofA/Merrill. C was placed on the US 1 list, Bank of America/Merrill Lynch said. The company trades at a discount to its peers, but its recovery is clearly on track. $45 price target.
Celgene
(CELG) - Get Celgene Corporation Report
target raised at Jefferies to $94, Jefferies said. Abraxane shows survival benefit. Buy rating.
Generac Holdings
(GNRC) - Get Generac Holdings Inc. Report
numbers raised at BMO. Shares of GNRC now seen reaching $42, BMO said. Estimates also increased on recent storm caused demand. Outperform rating.
Heartware
(HTWR)
estimates, target cut at UBS. Shares of HTWR now seen reaching $100, according to UBS. Estimates also reduced, given slower international growth and expected adoption of HVAD. Buy rating.
Medivation
(MDVN)
numbers raised at Jefferies. Shares of MDVN now seen reaching $62, Jefferies said. Estimates also raised on Xtandi beat. Buy rating.
Pfizer
(PFE) - Get Pfizer Inc. Report
numbers lowered at Jefferies. Shares of PFE now seen reaching $27, Jefferies said. Estimates also lowered on revenue miss. Buy rating.
STRATEGY CALLS / MARKET CALLS
Technology and Media sectors downgraded at Wells from market-weight to underweight, Wells Fargo said. The Media sector was also cut from Overweight to Market-weight. Groups are leveraged to slower business spending.
>To submit a news tip, email:
.
READERS ALSO LIKE:
>>Microsoft's Windows 8: Why I Changed My Mind
>>FDA Places New Heart-Safety Hurdle in Path of Opioid Constipation Drugs
Follow
TheStreet
on
and become a fan on
This article was written by a staff member of TheStreet.
